Dominari (NASDAQ:DOMH) Lowered to "Sell" Rating by Wall Street Zen

Dominari (NASDAQ:DOMH - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Thursday.

Dominari Price Performance

NASDAQ DOMH traded down $0.12 during trading on Thursday, hitting $4.48. The company's stock had a trading volume of 171,516 shares, compared to its average volume of 1,253,043. Dominari has a fifty-two week low of $0.83 and a fifty-two week high of $13.58. The company has a market cap of $65.61 million, a PE ratio of -1.16 and a beta of 0.59. The business's 50 day simple moving average is $4.62 and its 200-day simple moving average is $3.85.

Dominari (NASDAQ:DOMH - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $0.20 EPS for the quarter. The firm had revenue of $6.56 million during the quarter. Dominari had a negative net margin of 180.22% and a negative return on equity of 32.89%.

Institutional Investors Weigh In On Dominari

A hedge fund recently raised its stake in Dominari stock. Renaissance Technologies LLC lifted its position in Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) by 20.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,326 shares of the company's stock after acquiring an additional 9,400 shares during the period. Renaissance Technologies LLC owned 0.89% of Dominari worth $55,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 42.48% of the company's stock.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.